Building on our two recent reports on Switzerland, this special Part III edition of Healthcare & Life Sciences Review casts a broad eye over the myriad of niches and specializations within the sector in which Switzerland and Swiss companies excel.

Notable topicalities include Novartis Oncology’s ground-breaking CAR-T therapy; how SwissMedic is leading the world in terms of regulatory innovation; the story of Actelion’s acquisition by J&J and the subsequent emergence of a new entity – Idorsia; Switzerland’s emergence as a destination for elite-level outsourced manufacturing; and the country’s embrace of digitally disruptive technologies throughout the pharmaceutical value chain, as evinced by SwissPost’s use of drones for drug deliveries.